Brief: Calithera Biosciences Inc To Reduce Workforce By About 35%

Calithera Biosciences

04/01/2021 12:35

Jan 4 (Reuters) - Calithera Biosciences Inc  CALA.O :
    * CALITHERA BIOSCIENCES INC -
    * CALITHERA BIOSCIENCES - WILL CONTINUE TO ADVANCE
TELAGLENASTAT
KEAPSAKE TRIAL IN NON-SMALL CELL LUNG CANCER, ARGINASE INHIBITOR
CB-280 TRIAL IN CYSTIC FIBROSIS, EMERGING PIPELINE
    * CALITHERA BIOSCIENCES INC - DEDICATED TO ADVANCING
RANDOMIZED
KEAPSAKE TRIAL
    * CALITHERA BIOSCIENCES INC - WILL REDUCE WORKFORCE BY ABOUT
35%
    * CALITHERA BIOSCIENCES INC - EXPECTS CASH, CASH EQUIVALENTS
AND
INVESTMENTS TO BE ABOUT $115 MILLION AT DEC 31, 2020
    * CALITHERA BIOSCIENCES INC - EXPECTS CASH, CASH
EQUIVALENTS,
INVESTMENTS AS AT DEC 31, TO BE SUFFICIENT TO MEET CURRENT
OPERATING PLAN THROUGH 2022
    * CALITHERA BIOSCIENCES - ANTICIPATES ONE-TIME
SEVERANCE-RELATED
CHARGE ASSOCIATED WITH WORKFORCE REDUCTION TO BE ABOUT $1.3
MILLION - $1.5 MILLION

Source text for Eikon:  ID:nGNX5bCsyR 
Further company coverage:  CALA.O 

 ((Reuters.Briefs@thomsonreuters.com;))